|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||83.01 - 84.03|
|52 Week Range||43.68 - 84.03|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||32.51|
|Earnings Date||Aug 05, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||508.91|
Eurofins Technologies continues to develop a range of diagnostic solutions for COVID-19, particularly in response to the threat of emerging mutations. Today, we announce the launch of two new products: GSD NovaPrime® Plus SARS-CoV-2, a PCR test which can detect, in one reaction, key mutations of variants of concern, present for example in the UK variant; and GSD NovaType Select L452R SARS-CoV-2 (RUO) the first test of its type able to detect critical variants such as the Indian, USA and Californian variants. Eurofins Technologies will continue to invest in R&D to develop further reliable, high-quality testing solutions for the SARS-CoV-2 virus and its variants.
Eurofins Covid Testing Services Ltd (ECTS) are now officially an approved government provider for day 2 and day 8 PCR testing.
EAG Laboratories is expanding its medical device testing capabilities with a new 20,000 square-foot laboratory located in St. Louis, Mo.